

RESOURCES

PEOPLE

NexMed (Robbinsville, NJ) has named **Kenneth Anderson** vice president of commercial development. Mr. Anderson served as senior manager for marketing and director for worldwide business development at Bristol-Myers Squibb until 1997, and was most recently senior vice president, director of strategy and business development for Harrison Wilson & Associates, a consulting and marketing firm.

Paradigm Genetics (Research Triangle Park, NC) has announced the appointment of **Christopher W.W. Beecher** as director of metabolic profiling. Dr. Beecher was formerly with Ancile Pharmaceuticals, where he served as senior director of developmental chemistry.

Kurt Brunden, formerly vice president of research at Gliatech, has been appointed vice president of drug discovery at Athersys (Cleveland, OH).



Enchira Biotechnology (The Woodlands, TX) has announced the election of **Nancy T. Chang** to its board of directors. Dr. Chang is co-founder, chairman, and CEO of Tanox.

Joseph M. Davie has been appointed to the board of directors of Targeted Genetics (Seattle, WA). Dr. Davie most recently served as senior vice president, research, at Biogen. His appointment brings the number of board members to eight.

PharmQuest (San Jose, CA) has added **Ajit Gill** and **Jere Goyan** to its board of directors. Mr. Gill is president and CEO of Inhale Therapeutic Systems, and Dr. Goyan was formerly president and COO of Alteon. In addition, from 1979 to 1981, Dr. Goyan served as commissioner of the US Food and Drug Administration.

Nathan Goodman has been appointed senior vice president of 3rd Millennium (Cambridge, MA), a bioinformatics consultancy. Dr. Goodman headed the informatics core at the Whitehead Institute/MIT Center for Genome Research from 1991 to 1996, and led a group focused on bioinformatics applications in the pharmaceutical industry at Compaq Computer.

Leroy Hood has been appointed chairman of InforMax's (Rockville, MD) scientific advisory board. Dr. Hood was the William Gates III Professor of Biomedical Sciences and chairman of the department of molecular biotechnology at the University of Washington School of Medicine. Last year,

he founded the Institute for Systems Biology in Seattle.

MethylGene (Montreal, Quebec, Canada) has appointed **Klaus B. Kepper** as chief financial officer. Mr. Kepper comes to MethylGene after 15 years with Smith & Nephew, most recently as CFO of its German operation.

GeneMax Pharmaceuticals (Vancouver, BC, Canada) has announced the appointment of **Julia Levy** to its board of directors. Dr. Levy is president and CEO of QLT Inc., a position she has held since 1995.

Inhale Therapeutic Systems (San Carlos, CA) has named **Edward T. Mathers** to the new position of vice president, marketing and business development. Most recently, Mr. Mathers was vice president, e-business at Glaxo Wellcome.

Malcolm J. McKay has joined Cell Genesys (Foster City, CA) in the new position of vice president, quality and regulatory affairs. Dr. McKay served most recently as vice president, regulatory affairs at Celtrix Pharmaceuticals. Also, Cell Genesys announced the resignation of **David F. Broad**, vice president, development and manufacturing, to pursue other interests.

Steven M. Rauscher has been appointed president and CEO of Genome Therapeutics (Waltham, MA). Mr. Rauscher has been a member of the company's board of directors since 1993, and was most recently CEO of AmericasDoctor.com. In addition, **Richard Labaudiniere**, former global head of lead generation for Rhône-Poulenc Rorer (now Aventis), has been named Genome Therapeutics' senior vice president of R&D.

Thomas Prescott Russo has been named chief financial officer of EntreMed (Rockville, MD). Mr. Russo most recently served as CFO for Electronic Trading Solutions, and was previously with Ernst & Young's Capital Markets Group.

Structural Bioinformatics (San Diego, CA) has announced that **Michael J. Savage** has been appointed to its management advisory board. Mr. Savage previously served as president and CEO of Molecular Simulations.

Michael B. Stewart has joined ICOS (Bothell, WA) as vice president of clinical affairs. Previously, he was vice president of immunology, inflammation, pulmonary and dermatology at Bristol-Myers Squibb.